ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 1 disease
R. Fischer, N. van Doremalen, D. Adney, C. Yinda, J. Port, M. Holbrook, J. Schulz, B. Williamson, T. Thomas, K. Barbian, S. Anzick, S. Ricklefs, B. Smith, D. Long, C. Martens, G. Saturday, E. de Wit, S. Gilbert, T. Lambe, V. Munster
Abstract
We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observed a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 did not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals did not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus was detected in lungs of vaccinated animals. Histopathological evaluation showed extensive pulmonary pathology caused by B.1.1.7 or B.1.351 replication in the control animals, but none in the vaccinated animals. These data demonstrate the effectiveness of the ChAdOx1 nCoV-19 vaccine against clinical disease caused by B.1.1.7 or B.1.351 VOCs.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351
J. J. Clark, P. Sharma, … J. P. Stewart·bioRxiv·Mar 10, 2021
- A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters
B. Ying, T. L. Darling, … M. S. Diamond·bioRxiv·May 4, 2023
- Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing
J. E. M. van der Lubbe, S. K. Rosendahl Huber, … F. Wegmann·bioRxiv·Jan 8, 2021
- Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
D. Kurup, D. C. Malherbe, … M. J. Schnell·bioRxiv·Jan 19, 2021
- Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
R. Kulkarni, W.-C. Chen, … W. Chang·bioRxiv·Aug 3, 2021
- SARS-CoV-2 B.1.1.7 infection of Syrian hamster does not cause more severe disease and is protected by naturally acquired immunity
I. A. Nunez, C. Z. Lien, … T. Wang·bioRxiv·Apr 2, 2021